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Abstract 
Overt mitochondrial diseases associated with mitochondrial DNA mutations are characterized bya decline in mitochondrial respiratory 
function. Similarly, a progressive decline in mitochondrial respiratory function associated with mitochondrial DNA mutations i clearly 
evidenced in aged human subjects. This communication is concerned with the development of a rat model for the study of bioenergy 
decline associated with the ageing process and overt mitochondrial diseases. The model involves the treatment ofyoung rats with AZT to 
induce skeletal and cardiac myopathies. It has shown that there is a decline in soleus muscle function in vivo and that his decline is 
mirrored in the capacity of heart sub-mitochondrial p rticles to maintain bioenergy function. Coenzyme Qi0 and several analogs were 
administered with AZT as potential therapeutics for the re-energization f affected tissues. Coenzyme Q~o and especially decyl Q were 
found to be therapeutically beneficial by both in vivo improvement in soleus muscle function and in vitro cardiac mitochondrial 
membrane potential capacity. Sub-mitochondrial p rticles were also prepared from heart mitochondria of young and aged rats. The 
particles prepared from the aged rats were found to have a decreased ability to maintain membrane potential as compared to those derived 
from the young rats. 
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1. Introduction 
The occurrence of overt mitochondrial diseases (myopa- 
thies) associated with mitochondrial DNA (mtDNA) muta- 
tion was first recognized by the laboratory of Morgan- 
Hughes in 1988 [1]. Over the next few years (1988-1991), 
there was a rapid identification, albeit of apparently rare 
occurrence, of overt mitochondrial diseases associated with 
mtDNA mutation and mitochondrial bioenergy deficiency. 
They acquired exotic diagnostic labels, including Leber's 
hereditary optic neuropathy (LHON), chronic progressive 
external ophthalmoplegia (CPEO), Kearns Sayre syndrome 
(KSS), myoclonus epilepsy with ragged red fibers 
(MERRF) and mitochondrial encephalomyopathy with lac- 
tic acidosis and stroke-like episodes (MELAS). These 
hitherto uncommon diseases have now come into the 
mainstream of medicine with increasing numbers running 
into thousands being identified yearly since their features 
have become better ecognized. 
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A striking feature of the pathological mtDNA mutations 
is what might be considered their classical nature; the 
range and types of mutations associated with these human 
diseases have all been described several decades earlier as 
mutations occurring in yeast mtDNA [2]. These mutations 
range from large mtDNA deletions, characteristic of the 
yeast petite mutants, now recognized as commonly associ- 
ated with the KSS and CPEO syndromes. Mutational 
changes in the mtDNA encoding proteins of the oxidative 
phosphorylation complexes, denoted mit  - mutations, have 
been described by many laboratories working on yeast 
mitochondria, and these types of changes are now de- 
scribed as associated with human syndromes uch as 
LHON. Mutations in the tRNAs, so called syn- ,  are 
characteristic of MERRF and MELAS. From these overall 
considerations in 1989 Linnane and associates formulated 
the hypothesis that these types of mtDNA mutations will 
occur randomly and accumulate with age, leading to a 
progressive decline in the bioenergy capacity of 
tissues/organs [3]. This bioenergy decline was suggested 
to contribute significantly to the etiology and pathology of 
a range of age-associated degenerative diseases and to the 
general frailty of very advanced age. The degenerative 
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diseases would now be envisaged to include heart and 
vascular conditions, various encephalomyopathies, Parkin- 
son's disease, some types of adult onset diabetes mellitus 
and others. 
Linnane and associates in 1989 also included [3] the 
concept that tissue bioenergy mosaics will develop with 
age due to the random mutation and turn-over of mtDNA 
in post-mitotic tissues (muscle, brain, others) and also the 
segregation of the mitochondrial genome in mitotic tissues. 
The concept of tissue bioenergy mosaic entails the repre- 
sentation in tissues of a mosaic of cells containing mito- 
chondria with different bioenergy capacity. In such a mo- 
saic there will be a range of bioenergy capacity amongst 
cells in which some cells will have a high bioenergy 
capacity through to cells which will be severely energy 
deficient. These considerations and our subsequent data 
have lead to the concept of the Universality of the Bioener- 
getic Disease [4]. 
Linnane and associates [3] also suggested that the oxida- 
tive phosphorylation system of tissues could be partially 
re-energized by means of redox therapy, whereby specific 
redox substances, uch as coenzyme Ql0 (Q) and others, 
could ameliorate the consequences of the age-associated 
decline in electron transport function which is responsible 
for the decline in bioenergy capacity. At this time, the 
tissue energy mosaic has been confirmed by several abo- 
ratories using enzyme histochemical techniques [5-7], al- 
though these studies do not specifically demonstrate that 
mtDNA mutations contribute to the bioenergy mosaic; 
putatively, the involvement of nuclear DNA mutations 
could produce the same effect. However, recent work of 
our laboratory with in situ PCR techniques clearly demon- 
strates that the tissue bioenergy mosaic is strongly corre- 
lated with the tissue distribution of mtDNA mutations 
(Baumer, A. and Linnane, A.W., in preparation). In this 
paper we shall focus on recent developments of redox 
therapy with Q analogs, at the levels of intact laboratory 
animals, skeletal muscle performance and bioenergetic 
properties of isolated mitochondria. 
2. Results and discussion 
We have experimentally approached the problem of 
mitochondrial bioenergy decline and re-energization both 
at the physiological and molecular levels. AZT (zidovu- 
dine), the main drug of choice in the treatment of AIDS, is 
well known to induce in humans and rats severe skeletal 
and cardiac myopathies [8,9]. AZT inhibits mitochondrial 
DNA polymerase and consequently, prolonged treatment 
of patients or animals with AZT induces profound changes 
in structure and function of mitochondria which are remi- 
niscent of the pathological changes observed in a number 
of mitochondrial diseases and ageing. We have used AZT 
treatment of rats administered by intraperitoneal injection 
for the induction of myopathies as a model for the study of 
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Fig. 1. In vivo mean fatigue profiles of rat soleus muscle. Three groups of 
6 month old female rats (8-9 animals each) were treated aily with i.p. 
injections for 85-90 days as follows: (i) control group, injected with the 
surfactant HCO-60 (0.2 ml of 2% aqueous olution); (ii) a group injected 
with AZT (10 mg/kg  body weight/day) dissolved in 0.9% NaCI and 
simultaneously injected with HCO-60; (iii) a further group injected with 
the same concentration of AZT as in (ii) as well as QL0c (decyl Q) (see 
text) dissolved in 0.2 ml of 2% HCO-60. The mechanical force of the 
stimulated soleus muscle in vivo was recorded for a period of 1000 s as 
described (see text and [I0]); the bars indicate the data averaged among 
all the animals of the particular group. 
the progressive age-associated bioenergy decline of tissues 
and the subsequent re-energization of the tissues with Q 
analogs, both at the whole animal and the isolated mito- 
chondria levels. We also briefly describe the decline in 
bioenergy function of heart mitochondria isolated from 
aged rats as compared to young rats. 
Soleus muscle, a major muscle of the hindlimb, was 
chosen for the in vivo studies because it contains 85-90% 
type I fibers and 10-15% type IIA fibers. Type I fibers are 
slow-twitch with a high mitochondrial density and are 
normally highly resistant o fatigue; type IIA fibers are 
fast-twitch with a relatively high mitochondrial density and 
are also fatigue resistant. The performance of the soleus 
muscle was investigated in vivo in the anaesthetized rats 
(urethane); the muscle was surgically exposed and electri- 
cally stimulated via its nerve with the muscle blood supply 
maintained intact. Recording conditions were isometric 
with the muscle set at optimum length and distally at- 
tached to a strain gauge [10]. The fatigue profile of the 
muscle was determined by stimulation at 40 Hz for 330 ms 
every second (i.e. duty cycle one third of a second stimu- 
lated, two thirds rest) for periods up to 8000 s. The 
contractile responses and the muscle electromyographic 
(EMG) signal were recorded on tape and records captured 
on line with a computer based logging system. 
Experiments with the soleus muscle of young adult rats 
(Fig. 1) have shown that the muscle can maintain its force 
at approx. 70% of the initial force for over 8000 s (the data 
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Fig. 2. Membrane potential of rat heart ETP H isolated from AZT-treated animals. Sub-mitochondrial particles ETP H (electron transfer phosphorylating) 
were prepared from the frozen hearts of rats from the same groups used in the experiments of Fig. 1. Each ETP H preparation was derived from 
approximately four pooled rat hearts. Membrane potential was monitored at 630-601 nm with 3 /xM oxonol VI [12] in an Aminco-Chance dual 
wavelength spectrophotometer at 25°C with 0.17 mg/ml of particles, as described [13]. The dashed trace was obtained with particles prepared from 
animals treated with AZT, whereas the solid trace from animals treated with both AZT and Qt0c as in Fig. 1. The concentration f NADH and succinate 
were 0.1 and 20 mM, respectively. Antimycin (1 /zM) was added to collapse the membrane potential completely. The times of addition of these inhibitors 
are indicated by vertical arrows. 
shown is for 1000 s of stimulation). With such a stimulus 
regime, the EMG signal did not alter significantly after the 
first 150-200 s indicating that this initial reduction in 
muscle force was not attributable to failure of action 
potential propagation i  either the muscle or the nerve or 
to neuromuscular failure. Young rats (2 to 3 months old) 
were subjected to AZT treatment administered by intra- 
peritoneal injection at the rate of 10 mg/kg body wt. per 
day for up to 90 days, a dose comparable to that therapeu- 
tically used in human patients. Treatment with AZT clearly 
decreases the steady state level of soleus force perfor- 
mance (Fig. 1). The level of soleus muscle force that is 
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Fig. 3. Membrane potential of mitochondrial ETP H prepared from the hearts of young and aged rats. Each preparation was derived from four pooled rat 
hearts from animals of similar ages: young rats (5-6 months old), aged rats (34-36 months old). Conditions were identical to those in Fig. 2. The 
concentration f particles was adjusted to give the same rate of succinate: Q reductase activity (complex II) for each pooled preparation. Rotenone was 
added at a final concentration f 1 /xM to completely block the membrane potential generated by NADH. Note the time scale of the traces is shorter than 
that in Fig. 2 with all other indications as in Fig. 2. 
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maintained after the (150-200 s) initial decrease is about 
40% of the initial value. Several groups of rats in addition 
to receiving AZT were simultaneously injected with either 
coenzyme Q J0 or its analog propenyi-Q (2,3-dimethoxy- 
5-methyl-6-propenyl benzoquinone, Q3¢) at a rate of 2 
mg/kg body wt. per day, or decyl-Q (2,3-dimethoxy-5- 
methyl-6-decyl benzoquinone, Ql0c) (0.75 mg/kg per 
day). As shown in Fig. 1, muscle performance was essen- 
tially normal with those rats receiving AZT plus Q~0c- 
Although not shown in the figure, coenzyme Ql0 was not 
as effective as Ql0c in restoring muscle performance, 
while Q3c had no significant effect on improving the 
muscle functional decline as induced by AZT treatment. 
This is the first documented evidence that redox therapy 
with Q analogs can successfully ameliorate the energetic 
performance of whole tissue in vivo after mitochondrial 
damage induced by AZT. 
The observed ecline in soleus muscle function induced 
by AZT treatment and the restoration of the muscle perfor- 
mance by simultaneous Ql0c treatment can be directly 
correlated with an improvement in mitochondrial bioen- 
ergy function. Previous studies have shown that AZT 
preferentially accumulates in skeletal and cardiac muscle 
of rats after prolonged treatment and that the induced 
morphological changes in the mitochondria of both tissues 
is the same [9]. Heart mitochondria re more stable and 
robust than skeletal muscle mitochondria, therefore we 
have chosen to perform the enzymological studies in heart 
mitochondria isolated from the frozen heart tissue of the 
same rats utilized in the muscle physiology studies. 
ETP H (electron transfer phosphorylating sub-mitochon- 
drial particles) were prepared from heart mitochondria [11] 
isolated from AZT-treated rats and AZT plus Q10c treated 
rats. The membrane potential generated by NADH oxida- 
tion in the two preparations was measured with the optical 
probe oxonol VI [12] as recently described [13]. The 
particles from the AZT plus Qz0c treated rats clearly have 
a higher membrane potential than those rats treated with 
AZT alone (Fig. 2). The membrane potential signal from 
the AZT plus Q~0c treated rats was similar to that mea- 
sured in particles from untreated rats (data not shown). 
There was no observed ifference between the two groups 
of rats in the membrane potential as generated by succinate 
oxidation (Fig. 2) indicating that complex I is the major 
site of the bioenergy damage induced by AZT treatment. 
Parallel studies (again data not shown) demonstrate hat 
the electron transport activity of complex I is the most 
affected of the respiratory complexes by AZT treatment 
and can be restored with Qi0c administration. These in 
vitro data mirror those found in the in vivo soleus muscle 
function. 
Fig. 3 compares the membrane potential of heart ETP H 
prepared from young (5-6 months) and aged (34-36 
months) rats. The membrane potential generated by NADH 
and succinate is dramatically reduced in the particles pre- 
pared from aged rats as compared to those prepared from 
young rats. In the experiment shown in Fig. 3 the concen- 
tration of the particles prepared from young and aged rats 
were adjusted to have the same rate of complex II activity. 
Consequently, the data shown in Fig. 3 serve to emphasize 
the marked differences in the mitochondrial membrane 
potential generation of young and aged rats. The results 
obtained with aged rats are in notable contrast o those 
obtained in young rats treated with AZT (cf. Figs. 2 and 
3); the AZT effects are restricted to complex I whereas in 
the aged rats complexes III and IV are also involved in the 
bioenergy decline of the mitochondria. 
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